Takayo Matsumura

Takayo Matsumura

Auto-generated profile, based on publicly available information

Takayo Matsumura

Clinical Development Department, Maruho Co., Ltd , Kyoto

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 July 2023 in British Journal of Dermatology
Verified
Journal Article
Open access
AIAtsuyuki Igarashi
Atsuyuki Igarashi
TKToshio Katsunuma
Toshio Katsunuma
TMTakayo Matsumura
Takayo Matsumura
HKHiroshi Komazaki
Hiroshi Komazaki
FGfor the Nemolizumab-JP04 Study Group
for the Nemolizumab-JP04 Study Group
TNTaiji Nakano
Taiji Nakano
Background: Atopic dermatitis (AD) is a chronic, inflammatory skin condition affecting up to one-quarter of children. Uncontrolled pruritus associated with childhood AD, and the accompanying scratching, negatively impacts quality of life (QoL), sleep and development. The humanized monoclonal antibody nemolizumab, used concomitantly with topical agents, was shown to reduce pruritus and improve QoL in patients with AD aged ≥ 13 years. However, data relating to its efficacy and safety in younger children (aged < 13 years) have been lacking. Objectives: To evaluate the efficacy and safety of nemolizumab, administered concomitantly with topical agents, in Japanese paediatric patients (aged 6–12 years) with AD and inadequately controlled moderate-to-severe pruritus. Methods: This was a randomized, placebo-controlled, double-blind, parallel-group, multicentre, 16-week, phase III study. Patients aged ≥ 6 and < 13 years, with confirmed AD, and an inadequate pruritic response despite treatment with topical agents and oral antihistamines were randomly assigned (1 : 1) to receive nemolizumab 30 mg or placebo every 4 weeks (Q4W). The primary efficacy endpoint was the change in the weekly mean 5-level itch score from baseline to week 16; secondary efficacy endpoints were related to pruritus, indicators for AD and QoL. Safety was assessed via adverse events (AEs) and laboratory test results. Results: In total, 89 patients were enrolled, received either nemolizumab 30 mg (n = 45) or placebo (n = 44) Q4W, and completed the study. The mean patient age was 9.1 (SD 1.9) years, and mean duration of AD was 8.5 (2.7) years. The change in 5-level itch score from baseline to week 16 showed a statistically significant difference in the nemolizumab treatment group (−1.3) compared with placebo (−0.5; least-squares mean difference −0.8, 95% confidence interval −1.1 to −0.5; P < 0.0001). Improvements with nemolizumab were observed from the second day of administration. Secondary endpoints were in favour of nemolizumab. No AEs resulted in discontinuation, and the overall safety profile in patients aged 6–12 years was comparable with that in older patients (aged ≥ 13 years) with AD. Conclusions: Nemolizumab is a potential new treatment option for paediatric patients with AD whose pruritus has not been sufficiently improved with topical treatments and antihistamines.

11 May 2023 in Journal of Dermatological Treatment
Verified
Journal Article
Open access
KKKenji Kabashima
Kenji Kabashima
TMTakayo Matsumura
Takayo Matsumura
YHYoshiteru Hayakawa
Yoshiteru Hayakawa
MKMakoto Kawashima
Makoto Kawashima
FGfor the Nemolizumab-JP01 Study Group
for the Nemolizumab-JP01 Study Group
Data from the Japanese phase 3 Nemolizumab-JP01 study (JapicCTI-173740) found that nemolizumab in combination with topical treatments reduced pruritus associated with atopic dermatitis inadequately...

21 March 2025 in British Journal of Dermatology
Verified
Journal Article
Open access
HYHiroo Yokozeki
Hiroo Yokozeki
HMHiroyuki Murota
Hiroyuki Murota
TMTakayo Matsumura
Takayo Matsumura
Background: The biologic therapy nemolizumab has been shown to improve the signs and symptoms of prurigo nodularis (PN) to a significantly greater extent than placebo over 16 weeks of treatment. We now report efficacy and safety data over 68 weeks. Objectives: To evaluate the long-term impact of nemolizumab on pruritus, disease severity, quality of life (QoL) and topical corticosteroid (TCS) usage in patients with PN in Japan, and to confirm the safety profile. Methods: Asian patients aged ≥ 13 years were randomly assigned (1 : 1 : 1) to receive nemolizumab 30 mg, 60 mg or placebo, with concomitant medium-potency TCS, every 4 weeks for 16 weeks. For the subsequent 52 weeks, nemolizumab treatment was continued, while placebo-treated patients were reallocated to either the 30-mg or 60-mg nemolizumab groups. Efficacy outcome measures included the Peak Pruritus Numerical Rating Scale (PP-NRS), 5-level itch scale, Investigator’s Global Assessment (IGA), the number of prurigo nodules, Insomnia Severity Index, Dermatology Life Quality Index and use of TCS. Safety measures included the frequency of treatment-emergent adverse events (TEAEs). The trial was registered with the Japan Registry of Clinical Trials (jRCT2011200017). Results: In the modified intention-to-treat population (n = 226), nemolizumab provided sustained and continuing improvements in efficacy between weeks 16 and 68. In patients who received nemolizumab 30 mg, PP-NRS had decreased by 60.5% at week 16 and by 78.6% at week 68; respective decreases in the 60-mg group were 55.1% and 76.5%. Across all treatment groups, a large proportion of patients experienced improvements indicating a reduction from moderate-to-severe to mild pruritus, improvements in IGA indicating a reduction in PN severity, a decrease in the number of nodules, and rapid and durable improvements in sleep and daily life activities. Nemolizumab-treated patients were also able to reduce the daily quantity of medium-potency and higher TCS used by at least half. There was no indication of relapse in pruritus, PN severity or QoL scores following treatment cessation. Most TEAEs were mild and similar to those reported in prior studies. Conclusions: Nemolizumab elicited continuous and durable improvements across multiple measures of pruritus, PN severity and QoL over 68 weeks of treatment, with no new safety concerns.